Impact of triglyceride-glucose index on the long-term prognosis of advanced gastric cancer patients receiving immunotherapy combined with chemotherapy

Table 5 Comparison of features between the training and validation sets, n (%)

Characteristic	Test (n = 90)	Train (n = 210)	χ2	P value
Age, years			1.94	0.164
< 60	46 (51.11)	89 (42.38)
≥ 60	44 (48.89)	121 (57.62)
Sex			0.43	0.512
Female	43 (47.78)	109 (51.90)
Male	47 (52.22)	101 (48.10)
BMI, kg/m2			0.21	0.646
< 25	69 (76.67)	166 (79.05)
≥ 25	21 (23.33)	44 (20.95)
TyG			0.31	0.578
Low	47 (52.22)	117 (55.71)
High	43 (47.78)	93 (44.29)
Drinking history			0.24	0.627
No	63 (70.00)	141 (67.14)
Yes	27 (30.00)	69 (32.86)
Smoking history			1.58	0.209
No	67 (74.44)	141 (67.14)
Yes	23 (25.56)	69 (32.86)
ECOG			0.41	0.523
0	57 (63.33)	141 (67.14)
1	33 (36.67)	69 (32.86)
Site			0.08	0.772
Stomach	44 (48.89)	106 (50.72)
Gastric and esophageal binding	46 (51.11)	103 (49.28)
Histological			1.39	0.239
Adenocarcinoma	21 (23.33)	63 (30.00)
Other	69 (76.67)	147 (70.00)
CEA, ng/mL			3.70	0.054
< 3	34 (37.78)	56 (26.67)
≥ 3	56 (62.22)	154 (73.33)
AFP, ng/mL			1.83	0.176
< 15	72 (80.00)	181 (86.19)
≥ 15	18 (20.00)	29 (13.81)
CA-199, ng/mL			1.54	0.214
< 37	60 (66.67)	124 (59.05)
≥ 37	30 (33.33)	86 (40.95)
Liver metastasis			1.60	0.206
No	63 (70.00)	131 (62.38)
Yes	27 (30.00)	79 (37.62)
Peritoneal metastasis			0.73	0.392
No	75 (83.33)	166 (62.38)
Yes	15 (16.67)	79 (37.62)
EBV status			0.10	0.578
No-infect	75 (83.33)	178 (84.76)
Infect	15 (16.67)	32 (15.24)
PD-L1 expression			0.60	0.440
CPS < 5	13 (14.44)	38 (18.10)
CPS ≥ 5	77 (85.56)	172 (81.90)
MMR status			0.02	0.893
pMMR	4 (4.44)	7 (3.33)
dMMR	86 (95.56)	203 (96.67)

BMI: Body mass index; TyG: Triglyceride glucose; ECOG: Eastern Cooperative Oncology Group; CEA: Carcinoembryonic-antigen; AFP: Alpha-fetoprotein: CA-199: Carbohydrate antigen 199; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair.